Our study suggests that the similarity of traditional poor prognostic factors, such as high tumor grade and PR negativity, between patients in the EOBC and VEOBC groups and those with non-early-onset breast cancer indicates the presence of unknown genetic and biological factors related to resistance to CDK 4/6 inhibitors. The gene discussed is PGR; the disease is breast carcinoma.